OP
STLN

Omni Partners’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Omni Partners’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$615K Sell
61,724
-101,638
-62% -$1.08M 0.03% 182
2020
Q4 		$1.76M Buy
+163,362
New +$1.68M 0.1% 135

Other funds holding STLN

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return

Omni Partners's STLN Position: Q1 2021 in Review

Omni Partners reduced its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 62% in Q1 2021, selling an estimated $1.08M and leaving 61,724 shares worth $615K. The position accounts for 0.03% of the portfolio, ranked #182.

Omni Partners first reported a position in STLN in Q4 2020 and has held it in 2 quarters since. The position peaked at $1.76M in Q4 2020. 50 funds tracked by Wall St. Rank hold STLN as of Q1 2021.

  • Omni Partners held 61,724 shares of Starling Oncology Institute, Inc. Common Stock worth $615K as of Q1 2021.
  • Omni Partners sold 101,638 Starling Oncology Institute, Inc. Common Stock shares in Q1 2021, an estimated $1.08M.
  • Starling Oncology Institute, Inc. Common Stock made up 0.03% of Omni Partners's portfolio in Q1 2021, its #182 holding.
  • Omni Partners first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2020 and has held it in 2 quarters since.
  • Omni Partners's Starling Oncology Institute, Inc. Common Stock position peaked at $1.76M in Q4 2020.
  • 50 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2021.

Based on Omni Partners's 13F filing for Q1 2021, filed 17 May 2021.